Effectiveness, Acceptability and Feasibility of a Communication and Care Coordinator (CCC) Model in Facilitating Serious Illness Communication (SIC) and Care in Patients With Cancer (CCC-Cancer)
Evaluating the Effectiveness, Acceptability and Feasibility of a Communication and Care Coordinator (CCC) Model in Facilitating Serious Illness Communication (SIC) and Care in Patients With Cancer
The goal of this clinical trial is to evaluate the communication and care coordinator (CCC) model in a national cancer institute and assess the utility of the model in facilitating serious illness communication (SIC) and care for patients with cancer.
The study aims are:
- To assess the effectiveness of the CCC model in improving patient outcomes.
- To assess the effectiveness of the CCC model in increasing rates of SIC and advance care planning (ACP) record documentation.
- To assess the acceptability of the CCC model to patients and clinicians.
- To evaluate the feasibility of implementing a CCC model in oncology care.
Researchers will compare results from the CCC intervention arm and usual care arm, to see if the CCC model can help improve patient outcomes and facilitate SIC between patients and clinicians.
Patient participants will:
- Follow the assignment of their clinician, who will be assigned randomly to either the usual care group or the intervention group.
- Be assigned a CCC and receive 6 CCC sessions over the course of 3 months (if assigned to CCC intervention arm).
- Complete 3 study assessment visits at baseline, Week 6, and 3 months
- Be invited to a one-time interview to share their study experience (optional, if selected and if in CCC intervention arm).
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
Timely SIC may facilitate earlier preferred plan of care documentation and improve patients' sense of peacefulness, hopefulness, and connectedness with their clinicians. The primary goal of the study is to evaluate the CCC model in a national cancer institute and assess the utility of the model in facilitating SIC and care for patients with cancer through a stepped wedge cluster randomized trial. This approach delivers crucial, empirical insights into how SIC can be efficiently and effectively delivered and potentially allow larger scale implementation and dissemination of the CCC model in Singapore, as an effective model for delivering patient support and facilitating patient-clinician communication in patients with advanced cancer.
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Shirlyn NEO Hui Shan, MD, PhD
- Número de teléfono: 63065838
- Correo electrónico: shirlyn.neo.h.s@singhealth.com.sg
Copia de seguridad de contactos de estudio
- Nombre: Benton PT TAM, MSc
Ubicaciones de estudio
-
-
-
Singapore, Singapur, 168583
- Reclutamiento
- National Cancer Center, Singapore
-
Contacto:
- Shirlyn NEO Hui Shan, MD, PhD
-
Contacto:
- Número de teléfono: 63065838
- Correo electrónico: shirlyn.neo.h.s@singhealth.com.sg
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
Patient Participants
- Aged 21 and above
- Diagnosed with (a) advanced cancer (stage 3 or 4) or (b) non-advanced cancer, but at high risk of recurrence
- Able to speak English or Chinese, irrespective of race
Clinicians
- Oncologists who are at least of designation of associate consultant and above in NCCS
Exclusion Criteria:
Patient Participants
- Disoriented and thus not able to sign informed consent
- Diagnosed with untreated hearing or visual loss or psychiatric illness
- Active suicidal ideation
Clinicians
- Overseas/not practising in Singapore for a significant amount of time
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Investigación de servicios de salud
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: CCC Intervention Arm
Each participant will be assigned a CCC and receive 6 CCC sessions over the course of 3 months. |
CCC sessions will be on exploring participant's illness journey thus far, their concerns, values and priorities. |
|
Sin intervención: Usual Care Arm
Each participant will continue to be followed by the oncologist and receive usual care but will not receive CCC intervention. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Communication Quality
Periodo de tiempo: Baseline, Week 6 after Baseline, and 3 months Post Enrolment.
|
Feeling Heard and Understood Survey (FHU) is a validated 4-item scale that has been used in palliative care to measure effectiveness of the SIC conversations and the value of the therapeutic relationship between the care team and the patient. The lowest possible score is 0 and the highest possible score is 16, with a higher score indicating that the care team listens well, respects patient's needs, and provides clear communication. |
Baseline, Week 6 after Baseline, and 3 months Post Enrolment.
|
|
Quality of Life per FACT-G7
Periodo de tiempo: Baseline, Week 6 after Baseline, and 3 months Post Enrolment.
|
Functional Assessment of Cancer Therapy-General-7 Item version (FACT-G7) is a 7-item questionnaire designed to quickly and effectively capture the most relevant issues to cancer. FACT-G7 scores could potentially range from 0-28, with a higher score indicating a better quality of life. |
Baseline, Week 6 after Baseline, and 3 months Post Enrolment.
|
|
Health Utility
Periodo de tiempo: Baseline, Week 6 after Baseline, and 3 months Post Enrolment.
|
EuroQOL Group 5-Dimension (EQ-5D-5L) contains a 5-item descriptive system measuring 5 dimensions: mobility, self-care, usual activities, pain/ discomfort, anxiety/ depression; a visual analogue scale (VAS) measuring overall health status. EQ-5D Index Value (Utility Score) ranges from 0 to 1.0 with higher value indicating better health-related quality of life. The VAS ranges from 0 to 100, with higher scores reflecting better self-rated health. |
Baseline, Week 6 after Baseline, and 3 months Post Enrolment.
|
|
Spiritual Well-Being
Periodo de tiempo: Baseline, Week 6 after Baseline, and 3 months Post Enrolment.
|
Functional Assessment of Chronic Illness Therapy - Spiritual Well-Being 12 Item Scale (FACIT-Sp-12) is a validated 12-item survey that is commonly used in the palliative care setting. It has 3 subscales (meaning, peace and faith). Scores in each subscale can potentially range from 0-16 and the total scores can range from 0-48. A higher score indicates greater spiritual well-being, better ability to find purpose in life and drawing comfort from spiritual resources. |
Baseline, Week 6 after Baseline, and 3 months Post Enrolment.
|
|
Healthcare Utilization - Rate of Unplanned Acute Hospital Utilization
Periodo de tiempo: From Study Enrolment to 3 months Post Enrolment.
|
The rate of unplanned acute hospital utilization through the emergency department during the study will be collected. |
From Study Enrolment to 3 months Post Enrolment.
|
|
Healthcare utilization - Length of hospital stay
Periodo de tiempo: From Study Enrolment until Date of Death, up to 3 years.
|
Data on the length of stay in hospital (bed days) will be collected. |
From Study Enrolment until Date of Death, up to 3 years.
|
|
Healthcare utilization - Hospital Bill
Periodo de tiempo: From Study Enrolment until Date of Death, up to 3 years.
|
Data on hospital bill size will be collected. |
From Study Enrolment until Date of Death, up to 3 years.
|
|
Healthcare utilization - Type of oncological treatment
Periodo de tiempo: From 3 months prior to study enrolment until 3 months after study enrolment.
|
Data on the type of oncological treatment used will be collected. |
From 3 months prior to study enrolment until 3 months after study enrolment.
|
|
Healthcare utilization - Chemotherapy usage (line)
Periodo de tiempo: From Study Enrolment until Date of Death, up to 3 years.
|
Data on the line of chemotherapy (first, second or third or subsequent (fourth and onwards)) will be collected. |
From Study Enrolment until Date of Death, up to 3 years.
|
|
Healthcare utilization - Intensive care unit visit
Periodo de tiempo: From Study Enrolment until Date of Death, up to 3 years.
|
Data on the number of intensive care unit visits will be collected. |
From Study Enrolment until Date of Death, up to 3 years.
|
|
Healthcare utilization - Length of intensive care unit visit
Periodo de tiempo: From Study Enrolment until Date of Death, up to 3 years.
|
Data on the length of intensive care unit visits will be collected. |
From Study Enrolment until Date of Death, up to 3 years.
|
|
Healthcare utilization - High dependency unit visit
Periodo de tiempo: From Study Enrolment until Date of Death, up to 3 years.
|
Data on the number of high dependency unit visits will be collected. |
From Study Enrolment until Date of Death, up to 3 years.
|
|
Healthcare utilization - Length of high dependency unit visit
Periodo de tiempo: From Study Enrolment until Date of Death, up to 3 years.
|
Data on the length of high dependency unit visits will be collected. |
From Study Enrolment until Date of Death, up to 3 years.
|
|
Healthcare utilization - Location of death
Periodo de tiempo: From Study Enrolment until Date of Death, up to 3 years.
|
Data on the location of death will be collected. |
From Study Enrolment until Date of Death, up to 3 years.
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Acceptability - Satisfaction
Periodo de tiempo: 3 months Post Enrolment.
|
Client satisfaction survey is a 4-item, 4-point scale survey in which patients provide ratings on their satisfaction with the intervention, and their views on its relevance, timeliness, and impact. It has been validated in research studies in the outpatient setting around mental health support. Score can range from 4-16, with a higher score indicating greater client satisfaction. |
3 months Post Enrolment.
|
|
Feasibility - Approach-to-Enrolment Rates
Periodo de tiempo: From Commencement of Study Recruitment till the End of Recruitment, up to 24 months.
|
Approach-to-enrolment rates - where feasibility is defined that at least 60% of those patients approached could be enrolled into the study. |
From Commencement of Study Recruitment till the End of Recruitment, up to 24 months.
|
|
Feasibility - Patient Retention Rate
Periodo de tiempo: Baseline through Study Completion, estimated as up to 3 years.
|
Patient retention rate - where feasibility is defined that at least 80% of enrolled patients will be able to participate in the study for the planned study duration (3 months). |
Baseline through Study Completion, estimated as up to 3 years.
|
|
Effectiveness - SIC and ACP documentation
Periodo de tiempo: From Commencement of Study Enrollment through Study Completion, estimated as up to 3 years
|
The number of SIC and ACP documentation per clinician per enrolled patient during the study duration will be tracked during the intervention period(s) and during the control period(s). Clinical notes will also be read to evaluate if there was relevant documentation by clinician on SIC related issues. |
From Commencement of Study Enrollment through Study Completion, estimated as up to 3 years
|
|
Effectiveness - Time spent
Periodo de tiempo: From Commencement of Study Enrollment through Study Completion, estimated as up to 3 years
|
Time spent by CCC in this model and estimated time spent by clinicians on SICs will be collected. |
From Commencement of Study Enrollment through Study Completion, estimated as up to 3 years
|
|
Acceptability - Clinician experience
Periodo de tiempo: At end of intervention period (28th month).
|
Clinicians will be surveyed using a modified version of the Clinician Experience Survey (CES). The original CES was developed by Ariadne Labs for the purposes of assessing clinicians perceived feasibility and barriers in engaging patients in SIC. The researchers will modify the CES to form a 4-item scale (score range 4-16), with a higher score indicating greater clinicians' satisfaction with the CCC intervention. |
At end of intervention period (28th month).
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Silla de estudio: Shirlyn NEO Hui Shan, MD, PhD, National Cancer Centre, Singapore
Publicaciones y enlaces útiles
Publicaciones Generales
- Michie S, van Stralen MM, West R. The behaviour change wheel: a new method for characterising and designing behaviour change interventions. Implement Sci. 2011 Apr 23;6:42. doi: 10.1186/1748-5908-6-42.
- Curran GM, Bauer M, Mittman B, Pyne JM, Stetler C. Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact. Med Care. 2012 Mar;50(3):217-26. doi: 10.1097/MLR.0b013e3182408812.
- Sudore RL, Fried TR. Redefining the "planning" in advance care planning: preparing for end-of-life decision making. Ann Intern Med. 2010 Aug 17;153(4):256-61. doi: 10.7326/0003-4819-153-4-201008170-00008.
- Bernacki RE, Block SD; American College of Physicians High Value Care Task Force. Communication about serious illness care goals: a review and synthesis of best practices. JAMA Intern Med. 2014 Dec;174(12):1994-2003. doi: 10.1001/jamainternmed.2014.5271.
- Nikbakhsh N, Moudi S, Abbasian S, Khafri S. Prevalence of depression and anxiety among cancer patients. Caspian J Intern Med. 2014 Summer;5(3):167-70.
- Kumar P, Wixon-Genack J, Kavanagh J, Sanders JJ, Paladino J, O'Connor NR. Serious Illness Conversations With Outpatient Oncology Clinicians: Understanding the Patient Experience. JCO Oncol Pract. 2020 Dec;16(12):e1507-e1515. doi: 10.1200/JOP.19.00765. Epub 2020 Aug 4.
- Geerse OP, Lamas DJ, Sanders JJ, Paladino J, Kavanagh J, Henrich NJ, Berendsen AJ, Hiltermann TJN, Fromme EK, Bernacki RE, Block SD. A Qualitative Study of Serious Illness Conversations in Patients with Advanced Cancer. J Palliat Med. 2019 Jul;22(7):773-781. doi: 10.1089/jpm.2018.0487. Epub 2019 Feb 6.
- Paladino J, Koritsanszky L, Nisotel L, Neville BA, Miller K, Sanders J, Benjamin E, Fromme E, Block S, Bernacki R. Patient and clinician experience of a serious illness conversation guide in oncology: A descriptive analysis. Cancer Med. 2020 Jul;9(13):4550-4560. doi: 10.1002/cam4.3102. Epub 2020 May 4.
- Baxter R, Fromme EK, Sandgren A. Patient Identification for Serious Illness Conversations: A Scoping Review. Int J Environ Res Public Health. 2022 Mar 31;19(7):4162. doi: 10.3390/ijerph19074162.
- Agency for integrated care. Advance care planning. Accessed via: aic.sg/Care-Services/Advance-Care-Planning-ACP. Last accessed on February 6th 2026.
- Epstein AS, Riley M, Nelson JE, Bernal C, Martin S, Xiao H. Goals of care documentation by medical oncologists and oncology patient end-of-life care outcomes. Cancer. 2022 Sep 15;128(18):3400-3407. doi: 10.1002/cncr.34400. Epub 2022 Jul 22.
- Karim S, Levine O, Simon J. The Serious Illness Care Program in Oncology: Evidence, Real-World Implementation and Ongoing Barriers. Curr Oncol. 2022 Mar 2;29(3):1527-1536. doi: 10.3390/curroncol29030128.
- Malhotra C, Chaudhry I. Barriers to advance care planning among patients with advanced serious illnesses: A national survey of health-care professionals in Singapore. Palliat Support Care. 2024 Oct;22(5):978-985. doi: 10.1017/S1478951523000214.
- Ahluwalia SC, Levin JR, Lorenz KA, Gordon HS. Missed opportunities for advance care planning communication during outpatient clinic visits. J Gen Intern Med. 2012 Apr;27(4):445-51. doi: 10.1007/s11606-011-1917-0. Epub 2011 Oct 25.
- Shilling DM, Manz CR, Strand JJ, Patel MI. Let Us Have the Conversation: Serious Illness Communication in Oncology: Definitions, Barriers, and Successful Approaches. Am Soc Clin Oncol Educ Book. 2024 Jun;44(3):e431352. doi: 10.1200/EDBK_431352.
- Nagelschmidt K, Leppin N, Seifart C, Rief W, von Blanckenburg P. Systematic mixed-method review of barriers to end-of-life communication in the family context. BMJ Support Palliat Care. 2021 Sep;11(3):253-263. doi: 10.1136/bmjspcare-2020-002219. Epub 2020 Aug 27.
- Hanley S, Cotner CE, Fenton A, Wright AA, Manz CR. Barriers to Serious Illness Conversations Among Patients with Advanced Cancer: A Qualitative Study. J Pain Symptom Manage. 2025 Feb;69(2):183-189.e4. doi: 10.1016/j.jpainsymman.2024.10.034. Epub 2024 Nov 7.
- Martina D, Geerse OP, Lin CP, Kristanti MS, Bramer WM, Mori M, Korfage IJ, van der Heide A, Rietjens JA, van der Rijt CC. Asian patients' perspectives on advance care planning: A mixed-method systematic review and conceptual framework. Palliat Med. 2021 Dec;35(10):1776-1792. doi: 10.1177/02692163211042530. Epub 2021 Sep 6.
- Patel MI, Periyakoil VS, Blayney DW, Moore D, Nevedal A, Asch S, Milstein A, Coker TR. Redesigning Cancer Care Delivery: Views From Patients and Caregivers. J Oncol Pract. 2017 Apr;13(4):e291-e302. doi: 10.1200/JOP.2016.017327. Epub 2017 Feb 7.
- Patel MI, Kapphahn K, Dewland M, Aguilar V, Sanchez B, Sisay E, Murillo A, Smith K, Park DJ. Effect of a Community Health Worker Intervention on Acute Care Use, Advance Care Planning, and Patient-Reported Outcomes Among Adults With Advanced Stages of Cancer: A Randomized Clinical Trial. JAMA Oncol. 2022 Aug 1;8(8):1139-1148. doi: 10.1001/jamaoncol.2022.1997.
- Patel MI, Ramirez D, Agajanian R, Agajanian H, Coker T. Association of a Lay Health Worker Intervention With Symptom Burden, Survival, Health Care Use, and Total Costs Among Medicare Enrollees With Cancer. JAMA Netw Open. 2020 Mar 2;3(3):e201023. doi: 10.1001/jamanetworkopen.2020.1023.
- Lee ASY, Tang SN, Phua GLG, Yee AC, Neo SH. Adaptation of the Serious Illness Conversation Guide to Singapore's Multicultural Setting for Patients With Heart Failure, Renal Failure, or Cancer. Palliat Med Rep. 2024 Mar 26;5(1):122-126. doi: 10.1089/pmr.2023.0086. eCollection 2024.
- Ramakrishnan C, Lee ASY, Malhotra C, Phua GLG, Yee A, Neo SH. Adaptation of the serious illness conversation guide to a multicultural context in Singapore: a qualitative study. BMJ Open. 2025 Oct 23;15(10):e098264. doi: 10.1136/bmjopen-2024-098264.
- Ng A, Phua GL, Neo HS. Iterative adaptation and acceptability testing of the serious illness conversation guide for use with mandarin-speaking patients. Pal Med Rep. 2025 Nov;11(1):564-573.
- Ng A, Sivasamy V, Neo SHS. Cultural adaptation of the serious illness conversation guide for caregivers of persons with dementia in Singapore. BMC Geriatr. 2025 Dec 30;25(1):1075. doi: 10.1186/s12877-025-06761-4.
- Ng A, Yeo SM, Neo SH. Patient Readiness for Serious Illness Conversations: Identifying Psycho-Emotional Barriers Through a Phenomenological Lens. Psychooncology. 2025 Nov;34(11):e70317. doi: 10.1002/pon.70317.
- Gov.sg. Scribe. Accessed via: https://reports.open.gov.sg/scribe/overview Last accessed on February 9th, 2026.
- Chan HY, Leung DY, Lam PT, Ko PP, Lam RW, Chan KS. Effect of motivational interviewing to promote advance care planning among palliative care patients in ambulatory care setting: a randomized controlled trial. BMC Palliat Care. 2025 Jan 31;24(1):31. doi: 10.1186/s12904-025-01667-9.
- Edelen MO, Rodriguez A, Huang W, Gramling R, Ahluwalia SC. A novel Scale to Assess Palliative Care Patients' Experience of Feeling Heard and Understood. J Pain Symptom Manage. 2022 May;63(5):689-697.e1. doi: 10.1016/j.jpainsymman.2022.01.002. Epub 2022 Jan 10.
- Bandini JI, Schulson LB, Messan Setodji C, Williams J, Ast K, Ahluwalia SC. "Palliative Care Is the Only Medical Field That I Feel Like I'm Treated As a Person, Not As a Black Person": A Mixed-Methods Study of Minoritized Patient Experiences with Palliative Care. J Palliat Med. 2023 Feb;26(2):220-227. doi: 10.1089/jpm.2022.0237. Epub 2022 Aug 16.
- FACIT.org. Functional assessment of cancer therapy-general-7 item version. Accessed via: facit.org/measures/fact-g7. Last accessed on February 8th, 2026.
- EUROQOL. EQ-5D-5L. Accessed via: euroqol.org/information-and-support/euroqol-instruments-eq-5d-5l/. Last accessed on February 8th, 2026.
- FACIT.org. Functional Assessment of Chronic Illness Therapy - Spiritual Well-Being 12 Item Scale (FACIT-Sp-12). Last accessed via: https://www.facit.org/measures/facit-sp-12 Accessed on February 8th, 2026.
- CSQ scales. CSQ-4. Accessed via: https://csqscales.com/product/csq-04/ Last accessed on February 8th, 2026.
- Pedersen H, Skliarova T, Attkisson CC, Lara-Cabrera ML, Havnen A. Measuring patient satisfaction with four items: validity of the client satisfaction questionnaire 4 in an outpatient population. BMC Psychiatry. 2023 Nov 7;23(1):808. doi: 10.1186/s12888-023-05310-w.
- Ariadne Labs. ARIA. Accessed via: https://www.ariadnelabs.org/aria/ Last accessed February 2nd, 2026.
- Braun, V., & Clarke, V. (2006). Using thematic analysis in psychology. Qualitative Research in Psychology, 3(2), 77-101. doi.org/10.1191/1478088706qp063oa
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- 2026-1239
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .